SELLAS Life Sciences (SLS) Net Income Growth (3y) (2014 - 2026)
SELLAS Life Sciences (SLS) Net Income Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 47.10% |
| 10 | SELLAS Life Sciences | 1.86 Bn | 1.75 Bn | - | -9.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.77% |
| Dec 31, 2025 | 4.68% |
| Sep 30, 2025 | -0.17% |
| Jun 30, 2025 | -0.78% |
| Mar 31, 2025 | 28.08% |
| Dec 31, 2024 | 15.71% |
| Sep 30, 2024 | -1.63% |
| Jun 30, 2024 | -19.25% |
| Mar 31, 2024 | -60.77% |
| Dec 31, 2023 | -24.79% |
| Sep 30, 2023 | -27.25% |
| Jun 30, 2023 | -27.96% |
| Mar 31, 2023 | -39.82% |
| Dec 31, 2020 | 21.04% |
| Sep 30, 2020 | -244.58% |
| Jun 30, 2020 | -49.69% |
| Mar 31, 2020 | 23.87% |
| Dec 31, 2017 | -72.38% |
| Sep 30, 2017 | 26.92% |
| Jun 30, 2017 | 61.08% |